Clinical Outcome of Patients with Pelvic and Retroperitoneal Bone and Soft Tissue Sarcoma: A Retrospective Multicenter Study in Japan.
bone and soft tissue sarcoma
pelvis
prognosis
prognostic factors
retroperitoneum
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
20 Jun 2022
20 Jun 2022
Historique:
received:
23
05
2022
revised:
17
06
2022
accepted:
18
06
2022
entrez:
24
6
2022
pubmed:
25
6
2022
medline:
25
6
2022
Statut:
epublish
Résumé
This study aimed to retrospectively analyze the clinical outcomes of patients with pelvic and retroperitoneal bone and soft tissue sarcoma (BSTS). Overall, 187 patients with BSTS in the pelvis and retroperitoneal region treated at 19 specialized sarcoma centers in Japan were included. The prognostic factors related to overall survival (OS), local control (LC), and progression-free survival (PFS) were evaluated. The 3-year OS and LC rates in the 187 patients were 71.7% and 79.1%, respectively. The 3-year PFS in 166 patients without any distant metastases at the time of primary tumor diagnosis was 48.6%. Osteosarcoma showed significantly worse OS and PFS than other sarcomas of the pelvis and retroperitoneum. In the univariate analyses, larger primary tumor size, soft tissue tumor, distant metastasis at the time of primary tumor diagnosis, P2 location, chemotherapy, and osteosarcoma were poor prognostic factors correlated with OS. Larger primary tumor size, higher age, soft tissue tumor, chemotherapy, and osteosarcoma were poor prognostic factors correlated with PFS in patients without any metastasis at the initial presentation. Larger primary tumor size was the only poor prognostic factor correlation with LC. This study has clarified the epidemiology and prognosis of patients with pelvic and retroperitoneal BSTS in Japan.
Identifiants
pubmed: 35740688
pii: cancers14123023
doi: 10.3390/cancers14123023
pmc: PMC9221521
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Br J Radiol. 2014 Jan;87(1033):20130512
pubmed: 24288399
J Surg Oncol. 2006 Jul 1;94(1):81-7
pubmed: 16788949
Ann Surg. 2016 May;263(5):1002-9
pubmed: 26727100
Cancer Med. 2018 Sep;7(9):4308-4314
pubmed: 30030906
CA Cancer J Clin. 2020 May;70(3):200-229
pubmed: 32275330
J Clin Oncol. 1996 Mar;14(3):869-77
pubmed: 8622035
J Clin Oncol. 2003 Jul 15;21(14):2719-25
pubmed: 12860950
J Clin Oncol. 1996 May;14(5):1679-89
pubmed: 8622088
J Bone Joint Surg Am. 1978 Sep;60(6):731-46
pubmed: 701308
Int J Clin Oncol. 2016 Feb;21(1):186-93
pubmed: 26150259
Sarcoma. 2002;6(2):69-73
pubmed: 18521331
Sarcoma. 2015;2015:430576
pubmed: 26451129
Instr Course Lect. 1988;37:3-10
pubmed: 3047253
J Bone Joint Surg Br. 1999 Sep;81(5):796-802
pubmed: 10530839
Eur J Surg Oncol. 2004 Oct;30(8):893-9
pubmed: 15336737
Bone Joint J. 2013 Oct;95-B(10):1410-6
pubmed: 24078542
JAMA Netw Open. 2022 Jan 4;5(1):e2141927
pubmed: 34994795
Int J Radiat Oncol Biol Phys. 2018 Mar 15;100(4):972-979
pubmed: 29485077
Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):322-327
pubmed: 27084649
Cancer. 1998 Mar 1;82(5):851-9
pubmed: 9486573
Sarcoma. 2021 Dec 06;2021:8027314
pubmed: 34912177
J Clin Oncol. 2002 Feb 1;20(3):776-90
pubmed: 11821461
Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):367-374
pubmed: 28463156
Cancers (Basel). 2021 Mar 04;13(5):
pubmed: 33806515
Cancer. 2011 Jan 15;117(2):372-9
pubmed: 20830769
Cancer. 2012 Sep 15;118(18):4555-63
pubmed: 22359113
JB JS Open Access. 2018 May 29;3(2):e0064
pubmed: 30280138
Clin Orthop Relat Res. 1998 Mar;(348):196-207
pubmed: 9553553
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
J Orthop Sci. 2017 Jul;22(4):755-764
pubmed: 28601416
J Bone Joint Surg Br. 1997 Jul;79(4):553-7
pubmed: 9250737
Arch Pathol Lab Med. 2022 Mar 1;146(3):386-395
pubmed: 34319396
J Bone Joint Surg Am. 2006 Mar;88(3):575-82
pubmed: 16510825
Ann Surg. 1994 Feb;219(2):165-73
pubmed: 8129487
Cancers (Basel). 2020 Jul 19;12(7):
pubmed: 32707689